Arundic acid a potential neuroprotective agent: Biological development and syntheses

Current Medicinal Chemistry

Volumn 20, Issue 18, 2013, Pages 2315-2329

  Fernandes, Rodney A ^a   Ingle, Arun B ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Alzheimer's disease; Astrocyte modulation; Ischemic stroke; Neuroprotection; Parkinson's disease; Synthesis

Indexed keywords

APOLIPOPROTEIN E; ARUNDIC ACID; NEUROPROTECTIVE AGENT; PROTEIN S100B;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BINDING SITE; BRAIN ISCHEMIA; CELL ACTIVATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FOLLOW UP; HUMAN; LIVER FIBROSIS; LOW DRUG DOSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; ANIMALS; CAPRYLATES; DRUG DISCOVERY; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; STROKE;

EID: 84877977272     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320180003     Document Type: Article

References (58)

1. Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K.; Arrighi, H. M. Forecasting the global burden of Alzheimer's disease. Alzheimer's Dementia, 2007, 3, 186.
2. Feigin, V. L. Stroke epidemiology in the developing world. Lancet, 2005, 365, 2160.
3. Tateishi, N.; Mori, T.; Kagamiishi, Y.; Satoh, S.; Katsube, N.; Morikawa, E.; Morimoto, T.; Matsui, T.; Asano, T. Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part ii: Suppression of astrocytic activation by a novel agent (R)-()-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J. Cereb. Blood Flow Metab., 2002, 22, 723.
4. Sorbera, L. A.; Castaner, J.; Castaner, J. M. Arundic acid: Astrocyte-modulating agent, treatment of stroke, treatment of neurodegeneration. Drugs Future, 2004, 29, 441.
5. Shinagawa, R.; Tateishi, N.; Shimoda, T.; Maekawa, H.; Yada, N.; Akiyama, T.; Matsuda, S.; Katsube, N. Modulating effects of ONO-2506 on astrocytic activation in cultured astrocytes from rat cerebrum. Soc. Neurosci. Abs., 1999, 25, 843.10.
6. Katsumata, S.; Tateishi, N.; Kagamiishi, Y.; Shintaku, K.; Hayakawa, T.; Shimoda, T.; Shinagawa, R.; Akiyama, T.; Katsube, N. Inhibitory effect of ONO-2506 on GABA receptor disappearance in cultured astrocytes and ischemic brain. Soc. Neurosci. Abs., 1999, 25, 843.11.
7. Shimoda, T.; Tateishi, K.; Shintaku, K.; Yada, N.; Katagi, J.; Akiyama, T.; Maekawa, H.; Shinagawa, R.; Kondo, K. ONO-2506, a novel astrocyte modulating agent, suppresses the increase of COX-2 and iNOS mRNA expression in cultured astrocytes and ischemic brain. Soc. Neurosci. Abs., 1998, 24, 384.13.
8. Shinagawa, R.; Tateishi, N.; Shimoda, T.; Shintaku, K.; Yada, N.; Honjo, K. Kagamiishi, Y.; Kondo, K. ONO-2506 ameliorates neurodegeneration through inhibition of reduction of GLT-1 expression. Soc Neurosci Abs., 1998, 24, 384.14.
9. Beaulieu, C.; de Crespigny, A.; Tong, D. C.; Moseley, M. E.; Albers, G. W.; Marks, M. P. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: Evolution of lesion volume and correlation with clinical outcome. Ann. Neurol., 1999, 46, 568.
10. Chao, C. C.; Hu, S.; Sheng, W. S.; Bu, D.; Bukrinsky, M. L.; Peterson, P. K. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia, 1996, 16, 276.
11. Hu, J.; Castets, F.; Guevara, J. L.; Van Eldik, L. J. S-100 stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J. Biol. Chem., 1996, 271, 2543.
12. Hu, J.; Ferreira, A.; Van Eldik, L. J. S-100 induces neuronal cell death through nitric oxide release from astrocytes. J. Neurochem., 1997, 69, 2294.
13. Murphy, S. Production of nitric oxide by glial cells: Regulation and potential roles in the CNS. Glia, 2000, 29, 1.
14. Asano, T.; Tateishib, N. N.; Matsuia, T.; Moria, T.; Kagamiishib, Y.; Satob, S.; Katsubeb, N. Functional modulation of astrocytes by a novel agent ONO-2506 mitigates delayed infarct expansion with a wide therapeutic time window, inducing prompt neurological recovery through reduction of the extracellular level of glutamate. Int. Congr. Ser., 2003, 1252, 147.
15. Kato, H.; Araki, T.; Imai, Y.; Takahashi, Y.; Itoyama, Y. Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease. J. Neurol. Sci., 2003, 208, 9.
16. Kato, H.; Kurosaki, R.; Oki, C.; Araki, T. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res., 2004, 1030, 66.
17. Himeda, T.; Kadoguchi, N.; Kamiyama, Y.; Kato, H.; Maegawa, H.; Araki, T. Neuroprotective effect of arundic acid, an astrocytemodulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity. Neuropharmacol., 2006, 50, 329.
18. Burns, R. S.; Chiueh, C. C.; Markey, S. P.; Ebert, M. H.; Jacobowitz, D. M.; Kopin, I. J. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA., 1983, 80, 4546.
19. Heikkila, R. E.; Hess, A.; Duvoisin, R. C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science, 1984, 224, 1451.
20. Langston, J. W.; Ballard, P.; Tetrud, J. W.; Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-Analog synthesis. Science, 1983, 219, 979.
21. Oki, C.; Watanabe, Y.; Yokoyama, H.; Shimoda, T.; Kato, H, Araki, T. Delayed treatment with arundic acid reduces the MPTPinduced neurotoxicity in mice. Cell Mol. Neurobiol., 2008, 28, 417.
22. Mori, T.; Town, T.; Tan, J.; Tateishi, N.; Asano, T. Modulation of astrocytic activation by arundic acid (ONO-2506) mitigates detrimental effects of the apolipoprotein E4 isoform after permanent focal ischemia in apolipoprotein E knock-in mice. Cereb. Blood Flow Metab., 2005, 25, 748.
23. Hamanaka, H.; Katoh-Fukui, Y.; Suzuki, K.; Kobayashi, M.; Suzuki, R.; Motegi, Y.; Nakahara, Y.; Takeshita, A.; Kawai, M.; Ishiguro, K.; Yokoyama, M.; Fujita S. C. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum. Mol. Genet., 2000, 9, 353.
24. Mori, T.; Kobayashi, M.; Town, T.; Fujita, S. C.; Asano, T. Increased vulnerability to focal ischemic brain injury in human apolipoprotein E4 knock-in mice. J. Neuropathol. Exp. Neurol., 2003, 62, 280.
25. Mori, T.; Tateishi, N.; Kagamiishi, Y.; Shimoda, T; Satoh, S.; Ono, S.; Katsube, N.; Asano, T. Attenuation of a delayed increase in the extracellular glutamate level in the peri-infarct area following focal cerebral ischemia by a novel agent ONO-2506. Neurochem. Int., 2004, 45, 381.
26. Mori, T.; Town, T.; Tan, J.; Yada, N.; Horikoshi, Y.; Yamamoto, J. Shimoda, T, Kamanaka, Y.; Tateishi, N.; Asano T. Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J. Pharmacol. Exp. Ther., 2006, 318, 571.
27. Ohtani, R.; Tomimoto, H.; Wakita, H.; Kitaguchi,H.; Nakaji, K.; Takahashi, R. Expression of S-100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. Brain Res., 2007, 1135, 195.
28. Higashino, H.; Niwa, A.; Satou, T.; Ohta, Y.; Hashimoto, S.; Tabuchi, M.; Ooshima, K. Immunohistochemical analysis of brain lesions using S-100 and glial fibrillary acidic protein antibodies in arundic acid-(ONO-2506) treated stroke-prone spontaneously hypertensive rats. J. Neural. Transm., 2009, 116, 1209.
29. Kataoka, H.; Yamada, E.; Hazama, F. Increased basic fibroblast growth factor immunoreactivity in the brain of stroke-prone spontaneously hypertensive rats. Acta Neuropathol. (Berlin), 1994, 88, 7.
30. Steiner, J.; Bernstein, H. G.; Bielau, H.; Berndt, A.; Brisch, R.; Mawrin, C.; Keilhoff, G.; Bogerts, B. Evidence for a wide extraastrocytic distribution of S-100 in human brain. BMC Neurosci., 2007, 8, 2.
31. Pettigrew, L. C.; Kasner, S. E.; Albers, G. W.; Gorman, M.; Grotta, J. C.; Sherman, D. G.; Funakoshi, Y.; Funakoshi, H. Safety and tolerability of arundic acid in acute ischemic stroke. J. Neurol. Sci. 2006, 251, 50.
32. Ishibashi, H.; Pettigrew, L. C.; Funakoshi, Y.; Hiramatsu, M. Pharmacokinetics of arundic acid, an astrocyte modulating agent, in acute ischemic stroke. J. Clin. Pharmacol., 2007, 47, 445.
33. Data presented in Table 1 is taken from http://www.clinicaltrials.gov/.
34. Cui, W.; Wang, M.; Maegawa, H.; Teranishi, Y.; Kawada, N. Inhibition of the activation of hepatic stellate cells by arundic acid via the induction of cytoglobin. Biochem. Biophy. Res. Commun., 2012, 425, 642.
35. Kishimoto, K.; Nakai, H. Preparation of optically active 2-propyloctanoic acid as nerve degenerative disease inhibitors. Japan Patent 7-98328, 1995; Chem. Abstr., 1997, 126, 74487.
36. Kishimoto, K.; Nakai, H. Preparation of optically active 2-propyloctanoic acid. Japan Patent 7-102693, 1995; Chem. Abstr., 1997, 126, 74488.
37. Hasegawa, T.; Yamamoto, H. A practical synthesis of optically active (R)-2-propyloctanoic acid: Therapeutic agent for Alzheimer's disease. Bull. Chem. Soc. Jpn., 2000, 73, 423.
38. Hasegawa, T.; Kawanaka, Y.; Kasamatsu, E.; Iguchi, Y.; Yonekawa, Y.; Okamoto, M.; Ohta, C.; Hashimoto, S.; Ohuchida. S. Process development of ono-2506: A therapeutic agent for stroke and Alzheimer's disease. Org. Process. Res. Dev., 2003, 7, 168.
39. Hasegawa, T.; Yamamoto, H. Development of new chiral auxiliary derived from (S)-(-)-phenylethylamine for a synthesis of enantiopure (R)-2-propyloctanoic acid. Synthesis, 2003, 1181.
40. Wolfe, J. P.; Wagaw, S.; Buchwald, S. L. An improved catalyst system for aromatic carbon-nitrogen bond formation: the possible involvement of bis (phosphine) palladium complexes as key intermediates. J. Am. Chem. Soc., 1996, 118, 7215.
41. Wagaw, S.; Rennels, R. A.; Buchwald, S. L. Palladium-catalyzed coupling of optically active amines with aryl bromides. J. Am. Chem. Soc., 1997, 119, 8451.
42. Pelotier, B.; Holmes, T.; Piva, O. Synthesis of anti-Alzheimer (R)-arundic acid. Tetrahedron: Asymmetry, 2005, 16, 1513.
43. Piva, O.; Pete, J.-P. Diacetone D-glucose: Efficient chiral building block for asymmetric photodeconjugation. Tetrahedron: Asymmetry, 1992, 3, 759.
44. Bargiggia, F.; Dos Santos, S.; Piva, O. Asymmetric photodeconjugation: Highly stereoselective synthesis of-fluorocarboxylic derivatives. Synthesis, 2002, 427.
45. Bargiggia, F.; Piva, O. Anionic versus photochemical diastereoselective deconjugation of diacetone D-glucose ,-unsaturated esters. Tetrahedron: Asymmetry, 2003, 14, 1819.
46. Hasegawa, T.; Kawanaka, Y.; Kasamatsu, E.; Ohta, C.; Nakabayashi, K.; Okamoto, M.; Hamano, M.; Takahashi, T.; Ohuchida, S.; Hamada, Y. A new process for synthesis of the astrocyte activation suppressor, ONO-2506. Org. Process. Res. Dev., 2005, 9, 774.
47. Katritzky, A. R.; Pilarski, B.; Urogdi, L. Efficient conversion of nitriles to amides with basic hydrogen peroxide in dimethyl sulfoxide. Synthesis, 1989, 949.
48. Goswami, D.; Chattopadhyay, A. Crotylation of (R)-2,3- cyclohexylideneglyceraldehyde: A simple strategy for the synthesis of enantiopure anti-Alzheimer (R)-Arundic acid. Lett. Org. Chem., 2006, 12, 922.
49. Garcia, J. M.; Odriozola, J. M.; Lecumberri, A.; Razkin, J.; Gonzalez, A. A concise and efficient route to the Alzheimer's therapeutic agent (R)-Arundic acid. Tetrahedron, 2008, 64, 10664.
50. Fernandes, R. A.; Dhall, A.; Ingle, A. B. A diethyltartrate-based synthesis of both ()-and (+)-Arundic acid. Tetrahedron Lett., 2009, 50, 5903.
51. Johnson, W. S.; Werthemann, L.; Bartlett, W. R.; Brocksom. T. J.; Li, T.-T.; Faulkner, D. J.; Peterson, M. R. Simple stereoselective version of the Claisen rearrangement leading to trans-trisubstituted olefinic bonds: Synthesis of squalene. J. Am. Chem. Soc., 1970, 92, 741.
52. Ziegler, F. The thermal, aliphatic Claisen rearrangement. Chem. Rev., 1988, 88, 1423.
53. Fernandes, R. A.; Chowdhury, A. K. Total syntheses of all stereoisomers of phenatic acid B. J. Org. Chem., 2009, 74, 8826.
54. Fernandes, R. A.; Ingle, A. B. Chiral vicinal diols as platforms for separable diastereomers in Johnson-Claisen rearrangement: A new short route to ()-nor-canadensolide, ()-canadensolide and ()-sporothriolide. Tetrahedron Lett., 2009, 50, 1122.
55. Fernandes, R. A. An efficient synthesis of (-)-posticlure: the sex pheromone of Orygia postica. Eur. J. Org. Chem., 2007, 5064.
56. Fernandes, R. A.; Ingle, A. B.; Chaudhari, D. Control of diastereoselectivity in orthoester Johnson-Claisen rearrangement of tartrate-based allyl alcohol: An efficient synthesis of arundic acid, a potential therapeutic agent for Alzheimer's disease. Eur. J. Org. Chem., 2012, 1047.
57. Gualandi, A.; Emer, E.; Capdevila, M. G.; Cozzi, P. G. Highly enantioselective-Alkylation of aldehydes with 1,3-benzodithiolylium tetrafluoroborate: A formal organocatalytic-alkylation of aldehydes by the carbenium ion. Angew. Chem. Int. Ed., 2011, 50, 7842.
58. Afewerki, S.; Ibrahem, I.; Rydfjord, J.; Breistein, P.; Córdova, A. Direct regiospecific and highly enantioselective intermolecular- allylicalkylation of aldehydes by a combination of transition-metal and chiral amine catalysts. Chem. Eur. J., 2012, 18, 2972.